Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Hyman

Showing results (31-40 of 174) with videos related to

Pageof 18
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 1, 2014
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancerRachel N Grisham, Gopa Iyer, Evis Sala, et al.
Gynecologic Oncology|August 23, 2011
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancersDavid M Hyman, Qin Zhou, Angela G Arnold, et al.
JCO Precision Oncology|September 11, 2020
Specifying the True- and False-Positive Rates in Basket TrialsKristen M Cunanan, Alexia Iasonos, Ronglai Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2016
Basket Trials in Oncology: A Trade-Off Between Complexity and EfficiencyKristen M Cunanan, Mithat Gonen, Ronglai Shen, et al.
Journal of the American Medical Informatics Association : JAMIA|March 27, 2016
Automated eligibility screening and monitoring for genotype-driven precision oncology trialsMichael H Eubank, David M Hyman, Amritha D Kanakamedala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2018
Rates of <i>ERBB2</i> Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an <i>ERBB2</i>-Amplified Acral MelanomaLee S Gottesdiener, Shannon O'Connor, Klaus J Busam, et al.
Orphanet Journal of Rare Diseases|August 4, 2016
Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester diseaseEli L Diamond, Vaios Hatzoglou, Sneha Patel, et al.
Blood|August 10, 2013
Detection of an NRAS mutation in Erdheim-Chester diseaseEli L Diamond, Omar Abdel-Wahab, Elena Pentsova, et al.
Drug Discovery Today|September 1, 2015
Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trialsDavid M Hyman, David B Solit, Maria E Arcila, et al.
Gynecologic Oncology|January 1, 2013
Placental site trophoblastic tumor: analysis of presentation, treatment, and outcomeDavid M Hyman, Lauren Bakios, Gina Gualtiere, et al.
Pageof 18

Showing results (31-40 of 174) with videos related to

Sort By:
Pageof 18
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 1, 2014
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancerRachel N Grisham, Gopa Iyer, Evis Sala, et al.
Gynecologic Oncology|August 23, 2011
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancersDavid M Hyman, Qin Zhou, Angela G Arnold, et al.
JCO Precision Oncology|September 11, 2020
Specifying the True- and False-Positive Rates in Basket TrialsKristen M Cunanan, Alexia Iasonos, Ronglai Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2016
Basket Trials in Oncology: A Trade-Off Between Complexity and EfficiencyKristen M Cunanan, Mithat Gonen, Ronglai Shen, et al.
Journal of the American Medical Informatics Association : JAMIA|March 27, 2016
Automated eligibility screening and monitoring for genotype-driven precision oncology trialsMichael H Eubank, David M Hyman, Amritha D Kanakamedala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2018
Rates of <i>ERBB2</i> Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an <i>ERBB2</i>-Amplified Acral MelanomaLee S Gottesdiener, Shannon O'Connor, Klaus J Busam, et al.
Orphanet Journal of Rare Diseases|August 4, 2016
Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester diseaseEli L Diamond, Vaios Hatzoglou, Sneha Patel, et al.
Blood|August 10, 2013
Detection of an NRAS mutation in Erdheim-Chester diseaseEli L Diamond, Omar Abdel-Wahab, Elena Pentsova, et al.
Drug Discovery Today|September 1, 2015
Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trialsDavid M Hyman, David B Solit, Maria E Arcila, et al.
Gynecologic Oncology|January 1, 2013
Placental site trophoblastic tumor: analysis of presentation, treatment, and outcomeDavid M Hyman, Lauren Bakios, Gina Gualtiere, et al.
Pageof 18